The p53 tumor suppressor is activated after a wide variety of genotoxic stresses, resulting in cell cycle arrest, apoptosis or senescence 1, 2 . Inactivation of p53 is a common event in cancer 3, 4 and attempts to reactivate p53 function are being vigorously pursued as cancer therapeutics [5] [6] [7] [8] . However, in some cancers, including more than 99% of primary neuroblastomas, TP53 remains wild type 9 . After treatment with chemotherapy, alterations in p53 pathway components are frequently found to occur in neuroblastomas 9 . This suggests that complete inactivation of the p53 pathway is required for tumor cells to survive chemotherapy. How wild-type p53 can be tolerated by neuroblastoma cells before treatment is unclear, suggesting that other mechanisms exist to attenuate p53 function.
Changes in the abundance of p53 can modulate p53-mediated transcription 10, 11 and the resulting biological outputs, such as apoptosis [12] [13] [14] . Even modest decreases in p53 abundance can lead to greatly reduced activation of a p53 reporter gene in vivo 15 . Notably, 50% of the tumors that form in Trp53 +/− mice retain the wild-type Trp53 allele 16 , suggesting that a modest reduction in wild-type p53 promotes tumorigenesis.
The TP53 mRNA has a complex 3′ UTR, and highly conserved sequences within the 3′ UTR control TP53 translation through poorly understood mechanisms 17 . MiRNAs are small noncoding RNAs that control gene expression by regulating mRNA translation, stability or both, typically by binding regions of homology in the 3′ UTR of target mRNAs 18 . Several miRNAs with validated roles in the promotion or suppression of neoplasia have been identified 19, 20 .
Here we show that p53 is regulated in human cancer by miR-380-5p. We find that this miRNA is highly expressed in the majority of primary Inactivation of the p53 tumor suppressor pathway allows cell survival in times of stress and occurs in many human cancers; however, normal embryonic stem cells and some cancers such as neuroblastoma maintain wild-type human TP53 and mouse Trp53 (referred to collectively as p53 herein). Here we describe a miRNA, miR-380-5p, that represses p53 expression via a conserved sequence in the p53 3′ untranslated region (UTR). miR-380-5p is highly expressed in mouse embryonic stem cells and neuroblastomas, and high expression correlates with poor outcome in neuroblastomas with neuroblastoma derived v-myc myelocytomatosis viral-related oncogene (MYCN) amplification. miR-380 overexpression cooperates with activated HRAS oncoprotein to transform primary cells, block oncogene-induced senescence and form tumors in mice. Conversely, inhibition of endogenous miR-380-5p in embryonic stem or neuroblastoma cells results in induction of p53, and extensive apoptotic cell death. In vivo delivery of a miR-380-5p antagonist decreases tumor size in an orthotopic mouse model of neuroblastoma. We demonstrate a new mechanism of p53 regulation in cancer and stem cells and uncover a potential therapeutic target for neuroblastoma.
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neuroblastomas and functions as a proto-oncogene in a mouse mammary transplant model. miR-380-5p is predicted to bind to a highly conserved region in the TP53 3′ UTR. Inhibition of miR-380-5p results in upregulation of p53 in embryonic stem (ES) and neuroblastoma cells and the induction of apoptosis, as well as diminished tumor growth in vivo. Our results identify a new therapeutic approach to reactivate p53 in neuroblastoma.
RESULTS
The TP53 3′UTR has two potential binding sites for miR-380-5p
We identified a 104-bp region of high homology in the p53 3′ UTR shared across human, mouse, rat and hamster species but not conserved in nonmammalian species (Fig. 1a) . This corresponds to nucleotides (582-685) of the human TP53 3′ UTR. Human and mouse TP53 and Trp53 3′ UTRs share 78% identity within this region. This is similar to the 84% identity found when comparing the coding portion of human TP53 exon 11 with the corresponding sequence from mouse, suggesting that this region of the 3′ UTR may have functional importance. With the miRanda algorithm 21 we identified two predicted adjacent target sites for miR-380-5p within the conserved 3′ UTR region (Fig. 1a) at a spacing previously reported to enhance cooperative repression 22 . Local RNA structure is proposed to regulate the efficiency of miRNA binding to target UTRs 23, 24 . The sequence of both putative binding sites featured a preponderance of adjacent destabilizing structures (loops, single-stranded regions and free ends) and only short stem structures, features preferred for miRNA-3′ UTR interactions (Supplementary Table 1) . miR-380-5p is encoded within a large miRNA cluster found in an imprinted region of human 14q32 (ref. 25) . We detected abundant miR-380 expression in mouse embryonic tissue, human fetal tissue and adult human brain (Fig. 1b) , tissues in which p53 has key roles 26 , but not in other adult tissues. miR-380-5p was also highly expressed in mouse ES cells and P19 embryonic carcinoma cells, as determined by quantitative RT-PCR (Fig. 1c) . Human breast MCF10A cells do not express detectable miR-380-5p, and we used them as a negative control line (Fig. 1c) . MiR-380-5p expression was maintained in mouse ES cells differentiated in culture to Sox1 + neural progenitors and Tuj1 + neurons, but not in cultures containing predominantly Gfap + astrocytes (Fig. 1d-g ). Thus, miR-380-5p is not simply a marker of undifferentiated cells but is also expressed through neuronal specification.
miR-380-5p suppresses p53 and apoptosis in stem cells To examine the function of endogenous miR-380-5p, we used a locked nucleic acid (LNA)-modified antisense oligomer to inhibit miR-380-5p (LNA-380). Transfection of LNA-380, but not a control LNA, partially relieved repression of a luciferase reporter with three perfect miR-380-5p binding sites in the 3′ UTR (Fig. 2a) . Activity of a control reporter after transfection of miR-380-5p alone or with control LNA or LNA-380 was not changed (data not shown). Transfection of mouse ES cells with LNA-380 resulted in changes in ES cell morphology, diminished colony size, an increased number of nonadherent cells after 8 h (data not shown), and substantial cell death 24 h after treatment (Fig. 2b) . Although Trp53 −/− ES cells express similar levels of miR-380-5p to their wild-type counterparts, LNA-380 treatment of Trp53 −/− ES cells did not induce cell death (Fig. 2b,c) , demonstrating a requirement for p53 in cell death induced by LNA-380. Inhibition of miR-380-5p was accompanied by the upregulation of p53 protein and the apoptotic marker cleaved poly(ADP)-ribose polymerase (PARP) (Fig. 2d) in wild-type ES cells but not Trp53 −/− cells. We observed this effect over a range of LNA-380 concentrations but not in wild-type ES cells treated with a variety of scrambled and other control LNAs (Supplementary Fig. 1a-c) . As an additional control, we tested whether mature miRNAs are required for induction of p53 expression by LNA-380. ES cells that are deficient in mature miRNA species (including miR-380-5p, Fig. 2c ) owing to homologous deletion of DiGeorge syndrome critical region-8 (Dgcr8), remain responsive to genotoxic shock, and p53 expression is induced after ultraviolet irradiation (Fig. 2d) . However, treatment of Fig. 1d ). This increase in p53 protein is not due to stabilization of the protein, as the half-life of p53 is unchanged in LNA-380-treated cells compared to LNA-control-treated cells (Supplementary Fig. 1e ). In contrast, 4 h after ultraviolet irradiation, p53 protein was robustly stabilized (Supplementary Fig. 1e ). Amounts of the p53 regulators p19 ARF , Mdm2 and Chek2 were unchanged by LNA-380 treatment ( Supplementary Fig. 1f ). Fig. 1g ). Of note, endogenous expression of miR-380-5p but not another miRNA from the same genomic cluster (miR-323) or an unrelated miRNA (miR-16) decreased in a manner inversely correlated with p53 protein expression ( Supplementary Fig. 1g ). Although little is known about the transcriptional control and regulation of mature miR-380-5p stability, this suggests that ES cells have an built-in mechanism to minimize miR-380-5p levels in situations of cellular stress.
Treatment of ES cells with ultraviolet radiation leads to the rapid accumulation of p53 (Supplementary

Ectopic expression of miR-380 is sufficient to suppress p53
We transfected human MCF10A cells, which express wild-type p53 but not detectable miR-380-5p, with miR-380-5p or a nontargeting control miRNA mimic ( Supplementary Fig. 2a ). Expression of miR-380-5p resulted in a significant ~40% decrease in basal p53 protein levels (Fig. 3a,b) . UV irradiation led to a dose-dependent increase in p53 protein expression that was suppressed by the expression of miR-380-5p (Fig. 3a,b) . There was no significant difference in TP53 mRNA levels after miR-380-5p overexpression (Fig. 3c) , suggesting a predominant role for the miRNA in the regulation of TP53 translation rather than mRNA stability. For comparison, we transfected cells with miR-125b, which has recently been suggested to target p53 (ref. 27 ), but we did not detect a significant effect of miR-125b on either TP53 mRNA or protein levels ( Supplementary  Fig. 2b,c) . We obtained similar results with MCF7 and MCF10A cell lines that stably express miR-380 or a scrambled miRNA control ( Supplementary Fig. 2d-g ). Together with our data from ES cells ( Fig. 2 and Supplementary Fig. 1 ), these results suggest that miR-380-5p acts to directly regulate p53 translation rather than the stability of the mRNA or protein.
We next asked whether miR-380 expression directly regulates p53 protein expression via the conserved 104-bp element within the TP53 3′ UTR predicted to encode the two miR-380-5p binding sites (Fig. 1a) . are results from at least three independent repeats; in c experiments were performed in triplicate. *P < 0.0009, **P < 0.03, ***P < 0.002, ****P < 0.05, *****P < 0.03, ******P < 0.001.
We generated a luciferase reporter construct that contains a single 104-bp wild-type human TP53 element downstream of the luciferase open reading frame (WT-p53) or a reporter construct in which the nucleotides complementary to the miR-380-5p seed sequences were deleted (MUT-p53). These reporter constructs lack the remainder of the TP53 3′ UTR that contains other previously identified translational regulatory elements 28, 29 . When the WT-p53 reporter was transfected along with miR-380 into human embryonic kidney cells, luciferase activity was decreased ~30% compared to cells transfected with a control vector (Fig. 3d) . Suppression of luciferase activity was not observed when the MUT-p53 reporter was transfected with miR-380 (Fig. 3d) . Thus, miR-380-5p can directly attenuate translation via elements found in the TP53 3′ UTR. We next asked whether miR-380 overexpression can regulate apoptosis. Twenty-four hours after treatment with two different DNA damaging agents, ultraviolet light or cisplatin, we observed significantly more cell death in control cells than in those expressing miR-380 (Fig. 3e,f) . We saw no appreciable cell death in the absence of ultraviolet light or cisplatin treatment (data not shown).
miR-380 blocks senescence and acts as an oncogene in vivo A stringent test of oncogene function in cancer is the ability to induce tumor formation de novo in mouse models. Loss of p53 function cooperates with activated HRAS expression to induce a variety of tumors, including mammary cancers 30, 31 . We tested whether expression of miR-380 can similarly cooperate with activated HRAS to transform primary mouse mammary epithelial cells (MMECs). The unique biology of the mammary gland enabled us to use a transplantation technique that rapidly generates transgenic mammary glands in vivo 32 and can be used as an in vivo model of cellular transformation in a system with an intact p53 pathway. MMECs from naive FVB/N mice were collected and cultured for 72 h, during which time the cells were infected with a retrovirus encoding activated HRAS and retrovirus encoding various small RNAs. Cells were subsequently transplanted into the cleared mammary fat pad of syngeneic mice (Supplementary Fig. 3a) . Expression of activated HRAS with either miR-380 or a small hairpin RNA that specifically targets mouse Trp53 33 (shRNA p53) resulted in downregulation of a key transcriptional target of p53, Cdkn1a (also known as p21 waf1 ); in contrast to cells expressing activated HRAS and a scrambled control miRNA (Supplementary Fig. 3b ). Mice receiving MMECs expressing activated HRAS plus a control retrovirus infrequently developed small tumors (Fig. 4a) . In contrast, expression of activated HRAS with either miR-380 or shRNA p53 resulted in a substantially greater frequency of tumor formation (Fig. 4a) . We saw no significant differences in tumor latency or growth rates between the shRNA p53 and miR-380 groups (Supplementary Fig. 3c) . Expression of miR-125b with activated HRAS resulted in even fewer tumors than in the control mice (Fig. 4a) , consistent with a role for miR-125b in attenuating the proliferation of breast epithelium 34 . We observed elevated levels of miR-380-5p expression in all tumors tested (Fig. 4b) , and the average expression across these tumors was within the physiological range of expression observed in primary neuroblastomas (Supplementary Fig. 4a) .
Tumors expressing activated HRAS plus control viral constructs were cystic in nature and mostly comprised inflammatory cell infiltrates (Fig. 4c) . In contrast, miR-380 or shRNA p53 expression together with activated HRAS resulted in solid rather than cystic tumors that were comprised predominantly of epithelial cells (Fig. 4c) . Activated HRAS has been shown to induce senescence in a variety of tumor models in a p53-dependent manner 8, 30 . Tumor cells expressing activated HRAS plus control (empty vector or scrambled control) stained positive for senescence-associated β-galactosidase (Fig. 4c) . In contrast, tumors expressing HRAS plus miR-380 or shRNA p53 did not express senescence markers (Fig. 4c) . p21 waf1 expression was higher in wild-type mouse mammary epithelial cells and tumor cells expressing activated HRAS plus control viral constructs, than in tumor cells that expressed HRAS and miR-380 or shRNA p53 (Fig. 4c,d ). These data are consistent with a role for miR-380 in promoting mammary tumorigenesis by suppressing the p53-and p21 waf1 -dependent oncogeneinduced senescence program initiated by activated HRAS.
miR-380-5p and outcome in MYCN-amplified neuroblastoma
Virtually all neuroblastomas have wild-type TP53 before treatment with chemotherapy, suggesting that the p53 pathway may be attenuated by another mechanism in these tumors 35 . We examined miR-380-5p and p53 expression in neuroblastoma cell lines and found that a majority express readily detectable levels of miR-380-5p, and cell lines with wild-type TP53 generally had low expression of p53 protein (Supplementary Fig. 4b ).
The MYCN gene is frequently amplified in human neuroblastomas, and overexpression of MYCN in transgenic mice directed by the tyrosine hydroxlase promoter (TH-MYCN) gives rise to neuroblastomas that recapitulate many features of the human disease 36 . Despite p53 being functional in these neuroblastomas, p53-driven apoptosis is minimal. Treatment of tumor-bearing mice with chemotherapy causes induction of p53, apoptosis and complete tumor remission 37 . TH-MYCN transgenic mice are among the most widely used in vivo models of human neuroblastoma, having been used extensively as a preclinical model with a proven good record in therapeutic validation [37] [38] [39] [40] [41] . These tumors are diverse primary cancers that, unlike cell lines, have not been through experimental clonal selection and years of in vitro culture. Notably, the mature miR-380-5p sequence and both miR-380-5p targets in the p53 3′ UTR are highly conserved between humans and mice. In the TH-MYCN transgenic neuroblastoma model, we found that miR-380-5p expression was on average fivefold higher in primary tumors compared to benign sympathetic nervous tissue taken from either wild-type or MYCN-transgenic mice before the onset of disease (Fig. 5a) .
We next examined miR-380-5p abundance in 205 primary human neuroblastoma samples collected from subjects before treatment with chemotherapy and compared it to human brain, the normal adult tissue with the highest expression of miR-380-5p (Fig. 1b) . We found that miR-380-5p was readily detectable in 203 (99%) of 205 primary neuroblastomas (Fig. 5b) and substantially overexpressed, relative to normal brain, in 155 (76%) of 205 primary neuroblastoma samples (Fig. 5b) . Expression of miR-380-5p did not correlate with individual age or tumor stage; however, tumors with MYCN amplification had significantly lower expression of miR-380-5p (P < 0.001). In these individuals, high miR-380-5p expression was associated with a significantly poorer outcome than in those with low expression of miR-380-5p ( Fig. 5c ; P = 0.004). In individuals without MYCNamplified tumors, miR-380-5p expression was not associated with clinical outcome (Supplementary Fig. 4c) . Furthermore, by analyzing miR-380 expression in both primary and secondary tumors, we conclude that miR-380-5p expression is maintained in distant metastases (Supplementary Fig. 4d) . The finding that individuals whose tumors have both MYCN amplification and miR-380-5p overexpression have especially poor outcomes is consistent with data from various experimental model systems showing cooperation between MYC overexpression and attenuation of the p53 pathway in tumorigenesis.
miR-380-5p attenuates p53 function in neuroblastoma
The association of miR-380-5p expression with poor outcome in human neuroblastoma samples suggested a functional role in tumorigenesis. We transfected LNA-380 or two LNA controls into the MYCN-amplified NBL-WS human neuroblastoma cell line, which retains wild-type TP53, and examined cell proliferation and p53 expression. Inhibition of miR-380-5p resulted in a marked upregulation of p53 and p21 waf1 and PARP cleavage ( Fig. 6a  and Supplementary Fig. 4e ). Diminished cellular viability after LNA-380 treatment was more pronounced than after treatment with the chemotherapeutic doxorubicin in these cells (Fig. 6b,c) . Inhibition of miR-380-5p also resulted in p53 induction and impaired cellular proliferation in another TP53-wild-type human neuroblastoma cell line, SHEP (Supplementary Fig. 4f,g ). In contrast, the BE(2)C line, taken from an individual at relapse and in which TP53 has acquired an inactivating mutation 35 , did not show any changes in cell viability in response to LNA-380 transfection (Fig. 6a,c) . We conclude that miR-380-5p expression has a key role in suppressing wild-type p53 in human neuroblastoma.
miR-380-5p antagonist causes diminished tumor growth
We next examined whether miR-380-5p antagonists could alter the growth of neuroblastoma in vivo in a relevant orthotopic model. For this purpose, we chose a chimeric miRNA antagonist oligomer (anti-miR) that was modified at the 2′ position of the sugar with either a fluoro or a methoxyethyl group and a full phosphorothioate backbone. This design has been shown to produce potent inhibition of miRNAs in vivo (ref. 42 (anti-miR380) or a control sequence twice weekly for 3 weeks (25 mg per kg body weight per injection). Treatment with antimiR380 led to a markedly decreased size and weight of neuroblastoma tumors ( Fig. 6d,e ; P = 0.01). Anti-miR380-treated tumors also had diminished miR-380-5p and increased p21 waf1 expression as compared to the control (Supplementary Fig. 5a,b) . No toxicity was noted for mice treated with either anti-mir380 or control anti-miRs for 3 weeks (data not shown). We conclude that systemic delivery of a miR-380 antagonist diminishes the growth of orthotopically transplanted primary neuroblastoma tumors.
DISCUSSION
We have found that miR-380-5p is abundantly expressed in ES cells and provides a constitutive cell survival function by repressing expression of p53. We find that miR-380-5p antagonists act preferentially in ES cells that retain wild-type p53, indicating that p53 is a relevant target of miR-380-5p for this function. ES cells have an especially rapid rate of proliferation, lacking normal G1 and G2 phases, indicating that growth control pathways are attenuated. ES cells, however, retain an intact p53-MDM2-ARF tumor suppressor response that can be rapidly activated in times of cellular stress. Expression of miRNAs, such as miR-380-5p, may allow temporary and tunable repression of p53 in stem cells, thus permitting rapid cellular proliferation and self renewal, without the risks associated with irreversible loss of p53 function that is frequently found in cancer cells. Consistent with a dynamic role for miR-380-5p in regulating responses to cellular stress, we find rapid downregulation of this miRNA after ultraviolet treatment of ES cells, which correlates with upregulation of p53 expression. Appropriate epigenetic imprinting of the locus encoding miR-380 has been recently shown to be crucial for the reprogramming of mouse fibroblasts into induced pluripotent stem (iPS) cells that are competent to give rise to a whole mouse 43 . The expression of transcripts from this region (as detected in ES cells) distinguishes iPS cells that will successfully contribute to chimeric mice from genetically identical iPS cells 43 . Repression of p53 expression promotes efficient iPS reprogramming 44 , but whether expression of miR-380-5p or other miRNAs encoded from this locus are essential in the generation of iPS cells remains to be elucidated.
We have used neuroblastoma as a model disease in which to test the role of miRNA regulation of p53 in cancer. We show that nearly all neuroblastoma tumors express miR-380-5p and that high expression correlates with poor prognosis in individuals with MYCN-amplified disease. In human neuroblastoma cell lines, inhibition of miR-380-5p increases p53 expression and induces apoptotic cell death (Supplementary Fig. 6 ). Although p53 is the target we have studied most extensively, miR-380-5p is likely to target multiple mRNAs. We do not identify other miR-380-5p targets in this study, but we cannot exclude the possibility that miR-380-5p has other mRNA targets, some of which may also be involved in control of proliferation or survival.
A rapidly growing body of evidence has identified miRNAs as potential targets for cancer therapy. For example, overexpression of miR-26 by adeno-associated virus in a MYC-driven liver cancer model can attenuate tumor formation 45 . Likewise, a transgenic model that conditionally expresses miR-21 was used to show that tumor formation and maintenance was miRNA dependent, as tumor regression occurred after miR-21 expression was switched off 46 . The development of small miRNA antagonists has opened the possibility for the use of druglike miRNA antagonists for cancer therapy. Inhibition of miR-10b by delivery of miRNA antagonists does not block primary tumor growth but can attenuate breast cancer metastasis in animal models 47 . Here we sought to determine whether miR-380 is required by tumors in vivo and found that treatment with anti-miR-380 results in diminished tumor growth. To our knowledge, this is the first report of decreased primary tumor growth in response to a systemically delivered in vivo treatment inhibiting a miRNA. We propose that miR-380 is an oncogene and a potential therapeutic target in p53 wild-type neuroblastoma. Specifically, whether inhibitors of miR-380-5p will sensitize tumors to genotoxic therapy is worth investigating in the clinic. 
METHODS
Methods
